Abstract Details

Title Neuropsychological Testing Identifies Patients with Pathologic Levels of ?-Amyloid in the Living Brain as Demonstrated by Florbetapir F18 Positron Emission Tomography

Topic Aging and Dementia

Presentation(s) P07 - (-)

Poster/Presentation
Number 141

Objective

Background BACKGROUND: The newly FDA-approved florbetapir F18 PET ligand with high affinity and specificity to ?-amyloid permits in vivo quantitative assessment of this objective biomarker of AD.

Design/Methods DESIGN/METHODS: A case series was conducted including 11 participants, aged 60 - 89 years, with histories of cognitive dysfunction. A neuropsychological test battery evaluating attention, executive functioning, language, motor speed, learning and memory was administered. A clinical diagnosis (i.e., amnestic MCI, AD, FTLD, vascular-related dementia or clinically normal) was made by neuropsychologists who were blind to PET findings. All participants underwent florbetapir PET scans for clinical evaluation which were visually scored by nuclear medicine as positive or negative for pathologic levels of ?-amyloid aggregation.

Results RESULTS: Five participants were diagnosed with amnestic MCI, 4 with FTLD, 2 with clinically normal presentations, and none with AD or vascular-related dementia. Positive florbetapir F18 PET scans were found in 4 of those with MCI; 0 of those with FTLD and 0 of those deemed normal.

Conclusions CONCLUSIONS: Findings suggest that neuropsychological testing has robust clinical utility in identifying patients with amnestic MCI who exhibit biomarkers of AD on florbetapir F18 PET imaging. These data underscore the benefit of neurometrics in the early identification process, thereby facilitating accurate diagnosis and informing treatment planning.

Authors/Disclosures
Heidi A. Bender, PhD (Mt Sinia School of Medicine, Neurology) PRESENTER	No disclosure on file
	No disclosure on file
Mary Sano, PhD (Mount Sinai Sch of Med & Bronx VA Med Ctr)	Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for Avenir. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen Idec. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for BioXcel. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for CogRx. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for Genentech. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for F. Hoffman LaRoche. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for Minerva Neuroscience. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for NovoNordisk. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for Pfizer. Dr. Sano has received personal compensation in the range of $0-$499 for serving as a Consultant for vTv Therapeutics. Dr. Sano has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Syneos. Dr. Sano has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Alzheimer's Association. Dr. Sano has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for International Psychogeriatric Association.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Martin Goldstein, MD (Union Square Practice)	No disclosure on file
Alastair Compston, PhD, FRCP	No disclosure on file
	No disclosure on file
Samuel E. Gandy, MD, PhD (Icahn SOM Mount Sinai)	No disclosure on file

��ɫ��

��ɫ��